Compounded medications should come with receipts. Here is how certificates of analysis and stability studies work — and a current sample from the licensed pharmacy network that fills Peptivik prescriptions.
This testing is performed by the licensed pharmacies and their testing partners, not by Peptivik, and is documented per lot in certificates of analysis. Which panels a given certificate reports varies by preparation — the certificate itself is the record.
Sampled from the dispensing network’s published COA library on November 11, 2026. Lots rotate as batches are produced and dispensed — these are examples of the documentation standard, not an inventory list, and not a claim about which lot fills a given prescription. Sermorelin, NAD+ and PT-141 have no current-dated lot in the network’s published library right now; their lots will appear here when the pharmacy publishes them.
| Lot | Strength | Vial | Expires | Compounding pharmacy |
|---|---|---|---|---|
| PGR-07102026-01 | 200 mg | Not listed | Jan 5, 2027 | PGRrx |
| PGR-30092026-01 | 200 mg | Not listed | Dec 29, 2026 | PGRrx |
| Lot | Strength | Vial | Expires | Compounding pharmacy |
|---|---|---|---|---|
| HT-14 | 2.5 mg / 0.5 mg (with B12) | 5 mL | Apr 15, 2027 | Hyalo Technologies |
| HT-15 | 2.5 mg / 0.5 mg (with B12) | 2 mL | Apr 14, 2027 | Hyalo Technologies |
| HT-16 | 2.5 mg / 5 mg (with glycine) | 5 mL | Apr 13, 2027 | Hyalo Technologies |
| HT-17 | 2.5 mg / 5 mg (with glycine) | 2 mL | Apr 12, 2027 | Hyalo Technologies |
| 0527202602 | 3.125 mg / 5 mg per mL (with glycine) | 4 mL | Nov 27, 2026 | Vital Rx |
| 0527202604 | 3.125 mg / 0.5 mg per mL (with B12) | 4 mL | Nov 27, 2026 | Vital Rx |
| 0527202605 | 2.5 mg / 0.5 mg per mL (with B12) | 2 mL | Nov 27, 2026 | Vital Rx |
| Lot | Strength | Vial | Expires | Compounding pharmacy |
|---|---|---|---|---|
| PGR-15102026-01 | 18 mg/mL | 4 mL | Apr 13, 2027 | PGRrx |
| PGR-14102026-01 | 18 mg/mL | 4 mL | Apr 12, 2027 | PGRrx |
| PGR-13102026-01 | 18 mg/mL | 4 mL | Apr 11, 2027 | PGRrx |
| PGR-05062026-01 | 18 mg/mL | 4 mL | Dec 2, 2026 | PGRrx |
| PGR-04062026-01 | 18 mg/mL | 4 mL | Dec 1, 2026 | PGRrx |
| PGR-02062026-01 | 18 mg/mL | 4 mL | Nov 29, 2026 | PGRrx |
| PGR-01062026-01 | 18 mg/mL | 4 mL | Nov 28, 2026 | PGRrx |
| AP-202644 | 18 mg/mL | 2 mL | Nov 26, 2026 | Apothecary |
| AP-202643 | 18 mg/mL | 2 mL | Nov 25, 2026 | Apothecary |
| AP-202641 | 18 mg/mL | 4 mL | Nov 22, 2026 | Apothecary |
| HT-26 | 72 mg | 4 mL | Jun 9, 2027 | Hyalo Technologies |
| HT-27 | 36 mg | 2 mL | Jun 4, 2027 | Hyalo Technologies |
| HT-24 | 36 mg | 2 mL | May 21, 2027 | Hyalo Technologies |
| HT-23 | 72 mg | 4 mL | May 19, 2027 | Hyalo Technologies |
| HT-22 | 36 mg | 2 mL | May 14, 2027 | Hyalo Technologies |
| HT-21 | 72 mg | 4 mL | May 12, 2027 | Hyalo Technologies |
| HT-20 | 18 mg | 1 mL | May 8, 2027 | Hyalo Technologies |
| HT-19 | 72 mg | 4 mL | May 2, 2027 | Hyalo Technologies |
| HT-18 | 36 mg | 2 mL | Apr 29, 2027 | Hyalo Technologies |
| HT-10 | 17 mg / 0.5 mg (with methylcobalamin) | 4 mL | Apr 17, 2027 | Hyalo Technologies |
| HT-11 | 17 mg / 0.5 mg (with methylcobalamin) | 2 mL | Apr 16, 2027 | Hyalo Technologies |
| HT-12 | 17 mg / 5 mg (with glycine) | 4 mL | Apr 16, 2027 | Hyalo Technologies |
| HT-13 | 17 mg / 5 mg (with glycine) | 2 mL | Apr 15, 2027 | Hyalo Technologies |
| 0528202607 | 17 mg / 5 mg per mL (with glycine) | 2 mL | Nov 28, 2026 | Vital Rx |
| 0527202606 | 17 mg / 5 mg per mL (with glycine) | 4 mL | Nov 27, 2026 | Vital Rx |
The network also publishes temperature-excursion studies — measured answers to what happens if a shipment spends time outside refrigeration. Published findings, as stated by the testing pharmacies:
| Study | Published finding | Dated |
|---|---|---|
| Tirzepatide — room temperature | Stable for 4 days at ambient temperature. | Mar 2026 |
| Tirzepatide — elevated temperature | Stable for 2 days at 40°C (104°F) — studied by two independent compounders. | May 2026 |
| Tirzepatide & semaglutide co-formulations (Hyalo) | Stable for 4 days at 60°C (140°F). | 2026–2027 lots |
| Semaglutide/glycine — temperature excursion, 0–60°C | Minor degradation observed only at 60°C by day 4. | Aug 2025 |
| NAD+ — room temperature | Stable for 45 days at 25°C (77°F). | Sep 2025 |
Excursion studies describe tested shipping scenarios — they are not storage instructions. Always follow the storage and handling directions on your medication label.
Every vial dispensed to you carries a lot number on its label. Email it to support@peptivik.com and we’ll request the certificate of analysis for that exact lot from the dispensing pharmacy.
Prescriptions through Peptivik are filled by state-licensed compounding pharmacies in our medical partner’s dispensing network; the pharmacy that fills a given prescription varies by state and product. Certificates of analysis and stability studies are documents produced and published by those pharmacies and their testing partners, reproduced here for education — Peptivik does not manufacture, compound, test, or handle medication. This page is educational and is not medical advice.